Bright Minds Biosciences (DRUG) Competitors $45.12 -0.32 (-0.69%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. ZYME, STOK, UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, and QUREShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Zymeworks (ZYME), Stoke Therapeutics (STOK), Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Zymeworks Stoke Therapeutics Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure Bright Minds Biosciences (NASDAQ:DRUG) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Which has more volatility and risk, DRUG or ZYME? Bright Minds Biosciences has a beta of -6.14, indicating that its stock price is 714% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Is DRUG or ZYME more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Bright Minds Biosciences' return on equity of -20.96% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.96% -20.66% Zymeworks -182.75%-23.00%-18.04% Does the media refer more to DRUG or ZYME? In the previous week, Bright Minds Biosciences had 5 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.83 beat Bright Minds Biosciences' score of 1.10 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders have more ownership in DRUG or ZYME? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, DRUG or ZYME? Bright Minds Biosciences has higher earnings, but lower revenue than Zymeworks. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.93-49.59Zymeworks$122.87M9.97-$118.67M-$0.97-16.81 Do analysts rate DRUG or ZYME? Bright Minds Biosciences presently has a consensus price target of $81.00, indicating a potential upside of 75.65%. Zymeworks has a consensus price target of $21.43, indicating a potential upside of 31.42%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 SummaryBright Minds Biosciences beats Zymeworks on 9 of the 15 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.49M$3.15B$5.76B$10.26BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-49.4121.4076.8426.62Price / SalesN/A459.04528.69125.58Price / CashN/A45.4037.1760.46Price / Book50.139.6913.856.32Net Income-$2.06M-$53.02M$3.29B$271.01M7 Day Performance9.35%1.76%1.49%2.75%1 Month Performance10.27%5.38%5.21%7.15%1 Year Performance3,474.81%9.72%83.43%28.02% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.287 of 5 stars$45.12-0.7%$81.00+79.5%+3,563.7%$317.62MN/A-48.51N/APositive NewsAnalyst ForecastZYMEZymeworks2.4902 of 5 stars$15.19+0.9%$21.43+41.1%+26.6%$1.14B$122.87M-10.13460Positive NewsSTOKStoke Therapeutics3.9327 of 5 stars$21.99+6.3%$25.57+16.3%+57.3%$1.13B$36.56M25.87100UPBUpstream Bio1.6028 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038SIONSionna Therapeutics2.8525 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035Gap UpHigh Trading VolumeORICOric Pharmaceuticals4.5359 of 5 stars$10.50-3.5%$17.29+64.6%+9.1%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.2197 of 5 stars$14.80-3.0%$30.00+102.7%+78.2%$1.05B$297.20M-113.85280News CoverageSYRESpyre Therapeutics2.18 of 5 stars$16.63-2.2%$53.40+221.1%-48.8%$1.03B$890K-4.8973News CoverageAnalyst ForecastSPRYARS Pharmaceuticals2.6781 of 5 stars$10.70+6.3%$32.50+203.7%-27.3%$995.18M$89.15M-21.8490Positive NewsPRAXPraxis Precision Medicines2.3056 of 5 stars$40.75-13.0%$85.88+110.7%-27.9%$985.99M$8.55M-3.32110High Trading VolumeQUREuniQure3.2917 of 5 stars$17.43-2.9%$37.45+114.9%+167.5%$984.86M$27.12M-4.45500 Related Companies and Tools Related Companies Zymeworks Competitors Stoke Therapeutics Competitors Upstream Bio Competitors Sionna Therapeutics Competitors Oric Pharmaceuticals Competitors Pharming Group Competitors Spyre Therapeutics Competitors ARS Pharmaceuticals Competitors Praxis Precision Medicines Competitors uniQure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts